Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Debio 1453P SAD and MAD in Healthy Adults
NCT07035769Phase 1Recruiting
- Sponsor
- Debiopharm
- Start
- Jun 2025
- Primary completion
- Oct 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of Debio 1453 (2 arms), sponsored by Debiopharm. Primary endpoint: Number of Participants Who Experienced Treatment-Emergent Adverse Events up to 15 months. Started Jun 2025; status: recruiting.
02
Drugs
Debio 1453
Beyond the preview
Go deeper on NCT07035769.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07035769.